Texas Governor-elect Gina Hinojosa: “It is not that I hate data centers. I hate the way they are taking advantage of Texas”
Asked whether data centers still have a future in Texas:
HINOJOSA: “Right. Well, we have always been a pro-business state in Texas. But what changes now with me as governor is it has to be a partnership that benefits Texans. And right now what has happened is data centers have moved into mostly rural communities and there are no rules and laws to protect Texans and Texans are being taken advantage of. So the difference is we will have laws to protect Texans and we need to stop what we’re doing with data centers until we have those protections. We can have a strong economy, strong industry and protections for the people of Texas. Those things are not mutually exclusive, and I’ll make sure as governor I lead to ensure that that happens.”
TAPPER: “So you’re not ruling out that data centers will be able to be built in Texas, it’s just you want there to be regulations to protect communities, is that right?”
HINOJOSA: “And that communities have a seat at the table to decide if and how these data centers come into their communities. Texas is like a country. We are so diverse in all the ways. Different communities have different needs. And those communities have to be able to walk away from the table to leverage what they need for their community. So absolutely, we need to make sure they are partners in this effort. And that has always been my position. It is not that I hate data centers. I hate the way they are taking advantage of Texas. And that stops when I’m governor.”
You went to fucking Stanford AND Cambridge, sit on a congressional subcommittee with INNOVATION in its name, and somehow your grand fucking idea is to make America stop innovating?
How the fuck do you get this far in life with such an unbelievably stupid understanding of technology LMFAO.
You can pry my GPU from my cold dead hands.
I think we need to reframe this because we’re getting a little distracted by the novelty of the org chart. The goal should be to concentrate capital behind drugs with the best chance of meaningfully changing care. Getting more companies to IND with fewer employees is useful, but it doesn’t tell us whether we’re doing that.
Here's a concrete example: One published model estimates roughly $40m in direct spending to get a candidate through Phase 2. Suppose AI cuts a $2m candidate-generation budget by 90%. If Phase 2 success falls from 30% to 27%, the expected cost per successful Phase 2 program, including earlier failures, actually rises from about $205m to $212m. You can make creating the molecule dramatically cheaper and still make getting a useful clinical result more expensive.
I’d be more interested in AI allowing a small number of exceptionally talented teams to evaluate more assets, design better studies, and make better decisions about what deserves funding. Including killing their own programs when the evidence warrants it, which gets a little awkward when your only asset is also the reason your company exists. There’s real value in having people who can challenge each other’s assumptions before committing tens of millions of dollars to find out which assumption was wrong.
Those programs still compete for experienced investigators, eligible patients, and clinical budgets. Creating another hundred companies doesn’t magically expand any of those.
I’m all for making exploration cheaper and letting unconventional founders take a shot. But once the spending gets serious, I suspect scaling the best people’s judgment through AI matters considerably more than proving you can run a biotech by yourself.
(The cost benchmark comes from a 2024 model: $11.8m nonclinical + $7.1m Phase 1 + $21m Phase 2, in 2018 dollars. The calculation includes its earlier-stage failure rates; the $2m component, 90% saving, and 30%→27% change are illustrative assumptions. Phase 2 costs cover the phase, not necessarily just the first proof-of-concept study. JAMA Network)
Hey grok “I am a little cold”
No problem bio hunter I know your exact profile for every weather condition, I see you are wearing a t-shirt today.
sit back and enjoy the ride. I have already keyed up your favorite playlist. Unless you want to listen to the biotech hangouts pod that just dropped.
Coming to your world very very soon
bill ackman on why large, boring companies now drop 25% in a day, something he says almost never happened when he started:
"a quarter of every american business, plus or minus, is owned by some combination of vanguard, state street and northern trust. when you shrink the float of a public company, the marginal buyer and seller is going to have more impact on the stock price."
"the marginal buyer and seller today is a citadel or a millennium. they operate with a large amount of leverage, very large gross books, and they're increasingly short-term."
"most investors are very short-term focused because they're compensated that way. they won't invest in a company unless they're confident the price is going to be higher on december 31st."
passive owns the float, pods set the price, and both are structurally unable to hold through a bad quarter. that inability is the opportunity.
Millions of kids pass through a school system that teaches them they can ignore deadlines, defy authority, neglect their responsibilities, and fail repeatedly without consequence.
Then we send them into society and expect employers, institutions, and the criminal justice system to supply the discipline we lacked the will to impose.
$IVVD COVID ripping now through south east. North Carolina numerous friends down. Other friends starting to ask about boosters. Most pretty knocked out 5-7 days. Seems booster question is only about “wanting to reduce severity” vs larger concern.
@smithy05261244 Dude total BS, Caligan does not due margin and as of today still up 12% on the year. A number of funds not in LQDA will be lower than 12% when the numbers come out next week.
@BiotechObserver@adamfeuerstein@kevin__mak 💯 understand that the StatNews article was fine, I understand Adam‘s point. But My view that the best people to explain the data is management, Q&A, slides. Sure they can and do spin. Plenty of time for journalist to comment later.
The better question is why would $QURE want to give StatNews an early look. More often than not it doesn't really help the company or investors. If anything it does the opposite.
Management should have just halted the stock, released the data, and had a conference call. I'm not sure why biotech teams ever give early looks to the StatNews. Management has a track record of not understanding wall street. $ABVX is the poster child. Ah but they are French aka to be expected.
Best policy, in my view: halt the stock, release the PR, do the conference call, let everybody digest the slides, reopen the stock post-call. That is in the best interest of retail investors.
*Nothing against Adam they did what was agreed.